1 results match your criteria: "George Elliot Hospital and University of Warwick[Affiliation]"
Dapagliflozin: The outcome of use as add-on therapy in real-life clinical setting -An Audit.
J Pak Med Assoc
September 2021
George Elliot Hospital and University of Warwick, Coventry, UK.
Objective: Dapagliflozin is the first novel sodium glucose co transporter 2 inhibitor for the treatment of Type 2 diabetes. The aim of this audit was to evaluate its effectiveness and safety in a real-life clinical setting.
Methods: We analyze data from four UK district general hospitals on patients initiated on dapagliflozin.